Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

Item
http://www.wikidata.org/entity/Q36634305
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yesUnravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment optionsGefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplificationState of the art: Response assessment in lung cancer in the era of genomic medicineLocal ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or GefitinibTumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a "common language" for the new arena of cancer treatment.Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progressionMolecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Advanced non-small-cell lung cancer with epidermal growth factor receptor mutations: current evidence and future perspectives.Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.Translation in solid cancer: are size-based response criteria an anachronism?Immune-Related Tumor Response Dynamics in Melanoma Patients Treated with Pembrolizumab: Identifying Markers for Clinical Outcome and Treatment Decisions.Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis.
P2860

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

Item
http://www.wikidata.org/entity/Q36634305
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Radiographic assessment and th ...... GFR tyrosine kinase inhibitors
@ast
Radiographic assessment and th ...... GFR tyrosine kinase inhibitors
@en
type
label
Radiographic assessment and th ...... GFR tyrosine kinase inhibitors
@ast
Radiographic assessment and th ...... GFR tyrosine kinase inhibitors
@en
prefLabel
Radiographic assessment and th ...... GFR tyrosine kinase inhibitors
@ast
Radiographic assessment and th ...... GFR tyrosine kinase inhibitors
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P932
P356
P1433
P1476
Radiographic assessment and th ...... GFR tyrosine kinase inhibitors
@en
P2093
P2860
P304
P31
P356
10.1016/J.LUNGCAN.2012.11.007
P433
P478
P50
P577
P698
P932